Results 81 to 90 of about 28,830 (248)

SKI-1 and Furin Generate Multiple RGMa Fragments that Regulate Axonal Growth [PDF]

, 2012
SummaryThe nervous system is enormously complex, yet the number of cues that control axonal growth is surprisingly meager. Posttranslational modifications amplify diversity, but the degree to which they are employed is unclear.
Bermejo, Francisco Javier, Hassaine, M., Krivchikov, A. I., Pardo, L. C., Ramos, M. A., Romanini, M., Tamarit, J. L., Taylor, J. W., Vispa, A.   +8 more
core   +3 more sources

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome [PDF]

Diabetes & Metabolism Journal, 2018
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor.
Kwi-Hyun Bae, Sung Woo Kim, Yeon-Kyung Choi, Jung Beom Seo, Namkyun Kim, Chang-Yeon Kim, Won Kee Lee, Sungwoo Lee, Jung Guk Kim, In-Kyu Lee, Jang Hoon Lee, Keun-Gyu Park   +11 more
doaj   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression [PDF]

, 2013
Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health.
Deng, Chu-Xia, DePinho, Ronald A., Dong, X. Charlie, Tao, Rongya, Xiong, Xiwen   +4 more
core   +1 more source

Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines

Cell Reports Medicine
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.1 and Zhang et al.2 in Cell Reports Medicine and Cell Reports ...
Amirhossein Sahebkar, Maciej Banach
doaj   +1 more source

Transgenic Overexpression of the Proprotein Convertase Furin Enhances Skin Tumor Growth

Neoplasia: An International Journal for Oncology Research, 2012
Furin, one of the members of the family of proprotein convertases (PCs), ubiquitously expressed as a type I membrane-bound proteinase, activates several proteins that contribute to tumor progression.
Jian Fu, Daniel E. Bassi, Jirong Zhang, Tianyu Li, Emmanuelle Nicolas, Andres J.P. Klein-Szanto   +5 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis [PDF]

, 2016
Genome-wide association studies (GWAS) have revealed genetic determinants of iron metabolism, but correlation of these with clinical phenotypes is pending.
Aigner, Elmar, Arlt, Alexander, Becker, Thomas, Berg, Thomas, Boehm, Bernhard O., Braun, Felix, Buch, Stephan, D'Amato, Mauro, Datz, Christian, Dejaco, Christian, Erhart, Wiebke, Finkenstedt, Armin, Franke, Andre, Gallati, Sabina, Hampe, Jochen, Hinrichsen, Holger, Hultcrantz, Rolf, Kratzer, Wolfgang, Krawczak, Michael, Krones, Elisabeth, Lerch, Markus M., Mayerle, Julia, Nothnagel, Michael, Sahinbegovic, Enijad, Sarrazin, Christoph, Schafmayer, Clemens, Schaller, André, Sipos, Bence, Stadlmayr, Andreas, Stal, Per, Stickel, Felix, Strasser, Michael, Torkvist, Leif, Völzke, Henry, Zoller, Heinz, Zwerina, Jochen, Österreicher, Christoph   +36 more
core   +2 more sources

Potential of PCSK9 as a new target for the management of LDL cholesterol

Research Reports in Clinical Cardiology, 2015
Guiliana Mombelli, Samuela Castelnuovo, Chiara PavanelloCardiovascular Department, Dyslipidemia Center, Azienda Ospedaliera Niguarda Cà Granda, Milan, ItalyAbstract: A large proportion of patients at high risk for cardiovascular disease continue ...
Mombelli G, Castelnuovo S, Pavanello C
doaj  

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors [PDF]

Canadian Medical Association Journal, 2019
PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled ...
Derek, Leong, Peter E, Wu
openaire   +2 more sources